key: cord-0880945-8mv6w6b3 authors: Chauhan, Sanshriti; Meshram, Hari Shankar; Kute, Vivek; Patel, Himanshu; Banerjee, Subho; Engineer, Divyesh; Deshmukh, Sandeep; Dave, Ruchir title: SARS-CoV2 infection in chronic kidney disease vaccinated with Oxford/AstraZeneca COVID-19 vaccine: first report from India date: 2021-07-06 journal: Clin Kidney J DOI: 10.1093/ckj/sfab108 sha: 05b6ab926d948927db84fb5203879431265b0be9 doc_id: 880945 cord_uid: 8mv6w6b3 nan Severe acute respiratory distress syndrome coronavirus (SARS-CoV2) has grossly unsettled all aspects of humanity across the globe. As of May 2021, India is battling with the COVID-19 crisis and topping the world with the highest number of daily cases. 1 Additionally, the burden of chronic kidney disease (CKD) is amongst the highest in the world and has worsened further in the pandemic. 2 COVID-19 associated mortality has been reported higher in CKD compared to the general population. 3, 4 The vaccination campaign has progressed sleekly in the developed world relative to India which is still up against the herculean task of vaccinating such an enormous mass amid the COVID-19 surge. Indian advisories, till May 2021, have approved two vaccines Oxford Astraneza (COVIDSHIELD) and BBV152 (COVAXIN). The fear of sub-optimal antibody response to COVID-19 vaccines in chronic kidney disease was relieved by recent studies showing adequate immunogenicity of vaccines. 5, 6, However, with various vaccines available across the world and with diverse ethnicity, the antibody response and protection is expected to vary. Herein, we report our experience of SARS-CoV2 in CKD patients admitted in IKDRC-ITS, Ahmedabad, Gujarat, India who received either a single or two doses of Oxford Astraneza COVID-19 vaccine. To the best of our knowledge, this is the first such report. Overall, during the study period from 3-May 2021 to 10-May 2021, we detected ten vaccinated CKD patients (6 with 2 doses, and 4 with 1 dose) who contracted COVID-19. The median (interquartile range) age of the case series was 55(50-64) years with the majority being males (70%). Six patients were on maintenance hemodialysis. All of the patients had hypertension as a common co-morbidity. The SARS-CoV2 severity of the eight survived patients ranged from mild (n =3) to moderate (n=1) to severe (n=3). Most of the laboratory parameters were deranged in the study, except in patient 4 who was not investigated further after and was managed at home. Patients were managed mostly with oxygen support (n=7), anticoagulation (n=8), remdesivir (n=7) and steroids (n=5). Overall, two patients died and eight were discharged. Patient 2 had prior COVID-19 infection 8 months back and had a mild illness in both episodes. The median duration from the last dose of vaccine to onset of COVID-19 symptoms was 29(23-34) days. SARS-CoV2 antibody levels were > 40AU/ml in most cases except for the two patients who died and were on immunosuppression. The first noteworthy finding from our report is that the CKD patients on immunosuppression may have an inadequate response with the Oxford vaccine which makes them more prone to acquiring severe COVID-19. And the second is that the CKD patients are still susceptible to COVID-19 even with adequate antibody response. The different strains circulating are possibly responsible for this finding, but due to resource limitations, genomic sequencing was not completed. We suggest, continued research in the field of vaccine development and the impact of the vaccine on variants for assessing the real-world impact of vaccination. CKD group even though mounted a reasonable antibody response in our report, still acquired COVID-19. The protective cut-off antibody level is unknown in different ethnicity as the immune composition may vary in individuals of various geographic regions and so is the impact of variants. 7 There have been concerning reports of attenuated antibody response to mRNA COVID-19 vaccines in organ transplant recipients. 8 Similar to a previous report, 9 the three patients who were CKD and post-renal transplant status did not mount antibody response. In conclusion, we report the first study of COVID-19 in CKD patients vaccinated with the Oxford Astraneza vaccine emphasizing the need for expanded research with various vaccines and variants in this high-risk group of population. None declared. Data will be available from the corresponding author on reasonable request. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 We also express our sincere gratitude to all the resident doctors and health care staffs who are tirelessly doing a mammoth job of managing the COVID-19 cases in India, despite facing resource crisis. We additionally acknowledge the IT staff of the institute for helping in data retrieval for the study. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 Photos: India's daily Covid-19 cases cross 400,000 The adverse effect of COVID pandemic on the care of patients with kidney diseases in India CKD is a key risk factor for COVID-19 mortality Mortality in chronic kidney disease patients with COVID-19: a systematic review and metaanalysis Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis Systematic review of safety and efficacy of COVID-19 vaccines in patients with kidney disease COVID-19 vaccines and kidney disease Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients Seroconversion after COVID-19 vaccine in a patient on dialysis on immune suppressants